CFTR and cystic fibrosis: In patients with CF with a specific CFTR mutation (G551D) that impairs gating of the CFTR Cl− channel, treatment with VX-770 partially restored CFTR-mediated Cl− secretion in nasal epithelia and reduced airflow obstruction and pulmonary exacerbations related to CFTR dysfunction [47], [48].